Qiagen Shares Rise Premarket As Preliminary Q1 Results, Hikes FY25 EPS Guidance

Qiagen N.V. (NYSE:QGEN) shares are trading higher premarket on Monday. On Sunday, the company disclosed its preliminary results for the first quarter of 2025.

The company sees net sales growth of around 5% (+7% at constant exchange rates, CER) to about $483 million vs. consensus of $506.5 million.

The revenue figure surpassed the previously communicated outlook of about 3% CER growth (4% CER core business, excluding discontinued products such as NeuMoDx and Dialunox).

The company expects an adjusted EPS of at least $0.55 (vs. the street view of $0.56) in CER in the quarter, compared to prior guidance of about $0.50 CER.

Qiagen anticipates that the QuantiFERON latent TB test sales will increase by around 15% at CER, ...